HMTXF OTC
Hemostemix Inc
1W: -13.1%
1M: -20.9%
3M: +16.1%
YTD: -30.7%
1Y: -38.1%
3Y: -51.8%
5Y: -80.4%
$0.04
-0.00 (-0.08%)
Weekly Expected Move ±7.4%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$8.6M
52W Range0.035-0.08781
Volume220
Avg Volume9,959
Beta0.61
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOThomas A. Smeenk
Employees488
SectorHealthcare
IndustryBiotechnology
IPO Date2016-01-07
Websitehemostemix.com
707-7th Avenue SW
Calgary, AB T2P 3H6
CA
Calgary, AB T2P 3H6
CA
+1 905 580 4170
About Hemostemix Inc
Hemostemix, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing a proprietary autologous cell therapy to treat ischemic diseases. The firm's, ACP-01, lead clinical stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. The company was founded by Roger Bergersen and Thomas A. Smeenk in 2006 and is headquartered in Calgary, Canada.
Latest News
Hemostemix (CVE:HEM) Stock Price Crosses Above Fifty Day Moving Average – What’s Next?
Hemostemix (CVE:HEM) Share Price Crosses Below 50 Day Moving Average – Should You Sell?
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Recent Insider Trades
No insider trades found